Video

Safety Profile of S1P Receptor Modulators for Multiple Sclerosis

Author(s):

Krzysztof Selmaj, MD, PhD

Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).

Related Videos
Robert J. Fox, MD; Andreas Muehler, MD, MBA
Sarah Anderson, PharmD, NBC-HWC
Xavier Montalban, MD, PhD
Marcello Moccia, MD, PhD
Mikael Cohen, MD
Robert J. Fox, MD; Andreas Muehler, MD, MBA
Wallace Brownlee, MBChB, PhD, FRACP
Tom Fuchs, MD, PhD
Robert J. Fox, MD
Related Content
Hiding in Plain Sight: MS and Domestic Violence and Abuse
November 25th 2024

Hiding in Plain Sight: MS and Domestic Violence and Abuse

Rachel Horne Helen Ford, MD, MBChB Hons, FRCP
Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis
October 4th 2024

Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

Marco Meglio
This Week on NeurologyLive® — November 25, 2024
November 25th 2024

This Week on NeurologyLive® — November 25, 2024

NeurologyLive® Staff
Episode 120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve
July 26th 2024

Episode 120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve

Marco Meglio
Study Details of Phase 2 KYSA-6 Trial of CAR-T Therapy in Myasthenia Gravis Presented
November 22nd 2024

Study Details of Phase 2 KYSA-6 Trial of CAR-T Therapy in Myasthenia Gravis Presented

Marco Meglio
Research from IJMSC September 2024
November 18th 2024

Research from IJMSC September 2024

Erin E Gyomber
© 2024 MJH Life Sciences

All rights reserved.